Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Prehospital zalunfiban improves arterial patency, 30-day outcomes in STEMI
The novel glycoprotein IIb/IIIa inhibitor zalunfiban, administered at first medical contact in patients having ST-elevation myocardial infarction (STEMI), enhances patency of the infarct-related artery upon arrival in the catheterisation laboratory, in the phase III CeleBrate trial. It also improves 30-day cardiovascular (CV) outcomes, without increasing major bleeding.
Prehospital zalunfiban improves arterial patency, 30-day outcomes in STEMI
20 giờ trước
HCPs, patients willing to trade off OCS benefits to avoid side effects
Both patients and healthcare professionals prefer treatment for asthma attacks that avoids the side effects of oral corticosteroids (OCS), and both are willing to trade off benefits, according to a study.
HCPs, patients willing to trade off OCS benefits to avoid side effects
một ngày trước
ICONIC-LEAD affirms oral icotrokinra benefits in plaque psoriasis
In the phase III ICONIC-LEAD trial, selective blockade of the interleukin(IL)-23 receptor with the targeted oral peptide icotrokinra is associated with higher rates of skin clearance and symptom relief in adults and adolescents with moderate-to-severe plaque psoriasis.
